Table 1
| Drug (target) | Dizziness | Rash | AST/ALT increased | HC | HT | N/V | Diarrhea | Others |
|---|---|---|---|---|---|---|---|---|
| BMS-582949 (p38) | 19% | 4% | * | * | * | * | * | |
| Doramapimod (p38) | 3% | 3% | 5% | * | * | 5% | 3% | Headache 7% |
| Pamapimod (p38) | 15% | † | 7% | * | 0 | 5% | 5% | Neutrophilia 19% |
| Hematuria 14% | ||||||||
| Headache 6% | ||||||||
| CPK increased 3% | ||||||||
| Talmapimod (p38) | 6% | 14% | 1% | * | * | 8% | 5% | |
| VX-702 (p38) | * | * | 4% | * | * | * | 3% | Proteinuria 7% |
| Neutrophilia 3% | ||||||||
| VX-745 (p38) | 17% | * | 14% | * | * | ‡ | ‡ | |
| Tofacitinib (JAK) | 3% | 3% | 3% | 12% | 2% | 4% | 4% | Renal impairment 9% |
| Headache 7% | ||||||||
| LY3009104 (JAK) | * | * | * | 11% | * | * | 5% | Headache 11% |
| Fostamatinib (SyK) | 5% | 6% | 15% | § | 13% | 8% | 17% | Headache 8% |
| Neutropenia 7% | ||||||||
| Edema 4% | ||||||||
| Imatinib (cKit) | 7% | 29% | 10% | <1% | * | 55% | 42% | Fatigue 33% |
| Anemia 29% | ||||||||
| CPK increased 28% | ||||||||
| Edema 26% | ||||||||
| Headache 20% | ||||||||
| Masitinib (cKit) | * | 28% | 8% | * | <1% | 24% | 18% | Edema 21% |
| Headache 14% | ||||||||
| Fatigue 12% | ||||||||
| Pruritus 12% |
*Frequency of AE was not provided. †Rash was frequent but frequency was not provided. ‡Gastrointestinal disorders 14%. §Hypercholesterolemia was not significant in treated patients but frequency was not provided. AST, aspartate transaminase. ALT, alanine transaminase. CPK, creatinine phosphokinase. HC, hypercholesterolemia. HT, hypertension. N/V, nausea/vomiting.